Mid-Atlantic Epilepsy and Sleep Center   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Bethesda MD United States (2003)

Organization Overview

First Clinical Trial
2005
NCT01463033
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Mid-Atlantic Epilepsy and Sleep center | Mid-Atlantic Epilepsy and Sleep Center | Mid-Atlantic Epilepsy and Sleep Center, LLC

Active Ingredients

Drugs in Phase 4 Trials (2)

clobazam (onfi) (1 trial)

perampanel (fycompa) (2 trials)

Drugs in Phase 3 Trials (4)

ketamine (ketalar) (1 trial)

lacosamide (vimpat) (1 trial)

levetiracetam (keppra) (2 trials)

phenobarbital (Luminal) (1 trial)

Drugs in Phase 2 Trials (1)

orlistat (xenical) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Apnea (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Epilepsies, Partial (Phase 4)

Epilepsy (Phase 4)

Epilepsy, Post-Traumatic (Phase 2)

Obesity (Phase 2)

Seizures (Phase 4)

Sleep Apnea, Obstructive (Phase 2)

Sleep Apnea Syndromes (Phase 2)

Status Epilepticus (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 7